VANDA PHARMACEUTICALS INC. Deferred Income Tax Expense (Benefit)
VANDA PHARMACEUTICALS INC. (VNDA) reported Deferred Income Tax Expense (Benefit) of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-08-06
- VANDA PHARMACEUTICALS INC. deferred income tax expense (benefit) for the quarter ending 2026-06-30 was $0.00.
- VANDA PHARMACEUTICALS INC. deferred income tax expense (benefit) for the quarter ending 2026-03-31 was $0.00.
- VANDA PHARMACEUTICALS INC. deferred income tax expense (benefit) for the quarter ending 2025-12-31 was $103.19M.
- VANDA PHARMACEUTICALS INC. deferred income tax expense (benefit) for the quarter ending 2025-09-30 was -$5.97M.
- VANDA PHARMACEUTICALS INC. deferred income tax expense (benefit) for fiscal 2025 was $81.44M.
- VANDA PHARMACEUTICALS INC. deferred income tax expense (benefit) for fiscal 2024 was -$6.48M.
- VANDA PHARMACEUTICALS INC. deferred income tax expense (benefit) for fiscal 2023 was -$1.29M, a 213.81% decline from fiscal 2022.
- VANDA PHARMACEUTICALS INC. deferred income tax expense (benefit) for fiscal 2022 was $1.13M, a 83.25% decline from fiscal 2021.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $103.19M derived: sum of 3 quarters · filed 2026-08-06 | $97.21M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $103.19M derived: sum of 2 quarters · filed 2026-05-07 | $97.21M derived: sum of 3 quarters · filed 2026-05-07 | $89.24M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $103.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $97.21M derived: sum of 2 quarters · filed 2026-02-12 | $89.24M derived: sum of 3 quarters · filed 2026-08-06 | $81.44M 10-K · filed 2026-02-12 |
| 2025-09-30 | -$5.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$13.95M derived: sum of 2 quarters · filed 2026-08-06 | -$21.74M 10-Q · filed 2025-10-30 | -$23.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$7.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$15.77M 10-Q · filed 2026-08-06 | -$17.68M derived: sum of 3 quarters · filed 2026-08-06 | -$20.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$7.80M 10-Q · filed 2026-05-07 | -$9.71M derived: sum of 2 quarters · filed 2026-05-07 | -$12.80M derived: sum of 3 quarters · filed 2026-05-07 | -$14.03M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$1.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$5.00M derived: sum of 2 quarters · filed 2026-02-12 | -$6.24M derived: sum of 3 quarters · filed 2026-02-12 | -$6.48M 10-K · filed 2026-02-12 |
| 2024-09-30 | -$3.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$4.32M derived: sum of 2 quarters · filed 2025-10-30 | -$4.57M 10-Q · filed 2025-10-30 | -$12.05M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | -$1.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | -$1.48M 10-Q · filed 2025-07-31 | -$8.96M derived: sum of 3 quarters · filed 2026-02-12 | -$6.24M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | -$246.00K 10-Q · filed 2025-05-08 | -$7.73M derived: sum of 2 quarters · filed 2026-02-12 | -$5.00M derived: sum of 3 quarters · filed 2026-02-12 | -$3.55M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | -$7.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$4.75M derived: sum of 2 quarters · filed 2026-02-12 | -$3.30M derived: sum of 3 quarters · filed 2026-02-12 | -$1.29M 10-K · filed 2026-02-12 |
| 2023-09-30 | $2.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $4.18M derived: sum of 2 quarters · filed 2024-11-07 | $6.20M 10-Q · filed 2024-11-07 | $6.62M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-06-30 | $1.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $3.47M 10-Q · filed 2024-08-01 | $3.89M derived: sum of 3 quarters · filed 2025-02-14 | $2.05M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-03-31 | $2.01M 10-Q · filed 2024-05-09 | $2.43M derived: sum of 2 quarters · filed 2025-02-14 | $594.00K derived: sum of 3 quarters · filed 2025-02-14 | -$1.27M derived: sum of 4 quarters · filed 2025-02-14 |
| 2022-12-31 | $417.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | -$1.42M derived: sum of 2 quarters · filed 2025-02-14 | -$3.29M derived: sum of 3 quarters · filed 2025-02-14 | $1.13M 10-K · filed 2025-02-14 |
| 2022-09-30 | -$1.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$3.70M derived: sum of 2 quarters · filed 2023-11-09 | $713.00K 10-Q · filed 2023-11-09 | $2.03M derived: sum of 4 quarters · filed 2024-02-08 |
| 2022-06-30 | -$1.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-28 | $2.55M 10-Q · filed 2023-07-28 | $3.86M derived: sum of 3 quarters · filed 2024-02-08 | $6.39M derived: sum of 4 quarters · filed 2024-02-08 |
| 2022-03-31 | $4.42M 10-Q · filed 2023-05-03 | $5.73M derived: sum of 2 quarters · filed 2024-02-08 | $8.26M derived: sum of 3 quarters · filed 2024-02-08 | $10.00M derived: sum of 4 quarters · filed 2024-02-08 |
| 2021-12-31 | $1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-08 | $3.84M derived: sum of 2 quarters · filed 2024-02-08 | $5.58M derived: sum of 3 quarters · filed 2024-02-08 | $6.75M 10-K · filed 2024-02-08 |
| 2021-09-30 | $2.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $4.27M derived: sum of 2 quarters · filed 2022-11-03 | $5.43M 10-Q · filed 2022-11-03 | $7.83M derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-06-30 | $1.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $2.91M 10-Q · filed 2022-08-04 | $5.30M derived: sum of 3 quarters · filed 2023-02-09 | $7.08M derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-03-31 | $1.16M 10-Q · filed 2022-05-06 | $3.56M derived: sum of 2 quarters · filed 2023-02-09 | $5.33M derived: sum of 3 quarters · filed 2023-02-09 | $6.47M derived: sum of 4 quarters · filed 2023-02-09 |
| 2020-12-31 | $2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $4.17M derived: sum of 2 quarters · filed 2023-02-09 | $5.31M derived: sum of 3 quarters · filed 2023-02-09 | $6.19M 10-K · filed 2023-02-09 |
| 2020-09-30 | $1.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $2.91M derived: sum of 2 quarters · filed 2021-11-04 | $3.79M 10-Q · filed 2021-11-04 | $5.18M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $1.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $2.02M 10-Q · filed 2021-07-29 | $3.41M derived: sum of 3 quarters · filed 2022-02-24 | -$85.75M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $879.00K 10-Q · filed 2021-05-06 | $2.27M derived: sum of 2 quarters · filed 2022-02-24 | -$86.89M derived: sum of 3 quarters · filed 2022-02-24 | -$86.89M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$87.77M derived: sum of 2 quarters · filed 2022-02-24 | -$87.77M derived: sum of 3 quarters · filed 2022-02-24 | -$87.77M 10-K · filed 2022-02-24 |
| 2019-09-30 | -$89.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | -$89.16M derived: sum of 2 quarters · filed 2020-10-29 | -$89.16M 10-Q · filed 2020-10-29 | -$89.16M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $0.00 10-Q · filed 2020-08-06 | $0.00 derived: sum of 3 quarters · filed 2021-02-11 | |
| 2019-03-31 | $0.00 10-Q · filed 2020-05-07 | $0.00 derived: sum of 2 quarters · filed 2021-02-11 | ||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $0.00 10-K · filed 2021-02-11 | ||
| 2018-09-30 | $0.00 10-Q · filed 2019-11-07 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-26 | |||
| 2016-12-31 | -$104.00K 10-K · filed 2017-02-17 | |||
| 2011-12-31 | $1.82M 10-K · filed 2014-02-25 | |||
| 2010-12-31 | -$267.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | -$27.00K derived: sum of 2 quarters · filed 2013-02-26 | -$1.82M 10-K · filed 2013-02-26 | |
| 2010-09-30 | $240.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-07 | -$1.55M 10-Q · filed 2011-11-07 | ||
| 2010-06-30 | -$1.79M 10-Q · filed 2011-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |